<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02955355</url>
  </required_header>
  <id_info>
    <org_study_id>161505</org_study_id>
    <nct_id>NCT02955355</nct_id>
  </id_info>
  <brief_title>Long-Term Tolerability and Safety of HYQVIA/HyQvia in CIDP</brief_title>
  <official_title>Long-Term Tolerability and Safety of Immune Globulin Infusion 10% (Human) With Recombinant Human Hyaluronidase (HYQVIA/HyQvia) for the Treatment of Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Baxalta now part of Shire</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shire</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the long-term safety, tolerability, and immunogenicity
      of the subcutaneous (SC) treatment with Immune Globulin Subcutaneous (IGSC) facilitated with
      recombinant human hyaluronidase (rHuPH20) (HYQVIA/HyQvia) in participants with chronic
      inflammatory demyelinating polyradiculoneuropathy (CIDP) who have completed Baxalta Clinical
      Study Protocol 161403 Epoch 1 or Clinical Study Protocol 161601 without CIDP worsening.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2016</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants experiencing any treatment-emergent serious adverse events (SAEs) and/or adverse events (AEs), regardless of causality</measure>
    <time_frame>Throughout the study period of approximately 5 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants experiencing causally related serious adverse events (SAEs) and/or adverse events (AEs)</measure>
    <time_frame>Throughout the study period of approximately 5 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with serious and/or non-serious adverse reactions (ARs) plus suspected ARs</measure>
    <time_frame>Throughout the study period of approximately 5 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Rate of adverse events (AEs) that may be a result of immune-mediated responses</measure>
    <time_frame>Throughout the study period of approximately 5 years</time_frame>
    <description>Expressed as the number of events per infusion and per particpant-year</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of infusions associated with treatment-emergent serious adverse events (SAEs) and/or adverse events (AEs), regardless of causality</measure>
    <time_frame>Throughout the study period of approximately 5 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of infusions associated with causally related serious adverse events (SAEs) and/or adverse events (AEs)</measure>
    <time_frame>Throughout the study period of approximately 5 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of infusions temporally associated with adverse events (AEs)</measure>
    <time_frame>during or within 72 hours after completion of an infusion</time_frame>
    <description>Defined as AEs occurring during or within 72 hours after completion of an infusion</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of infusions associated with serious and/or non-serious adverse reactions (ARs) plus suspected ARs</measure>
    <time_frame>Throughout the study period of approximately 5 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of infusions associated with 1 or more systemic adverse events (AEs)</measure>
    <time_frame>Throughout the study period of approximately 5 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of infusions associated with 1 or more local infusion site reactions</measure>
    <time_frame>Throughout the study period of approximately 5 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of infusions for which the infusion rate was reduced and/or the infusion was interrupted or stopped due to intolerability and/or adverse events (AEs)</measure>
    <time_frame>Throughout the study period of approximately 5 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Rates of systemic and local AEs, regardless of causality</measure>
    <time_frame>Throughout the study period of approximately 5 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Rates of causally related systemic and local adverse events (AEs)</measure>
    <time_frame>Throughout the study period of approximately 5 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Rates of systemic and local adverse reactions (ARs) plus suspected ARs</measure>
    <time_frame>Throughout the study period of approximately 5 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with an adverse event (AE) that led to discontinuation from study</measure>
    <time_frame>Throughout the study period of approximately 5 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of moderate or severe adverse events (AEs) that may be a result of immune-mediated responses</measure>
    <time_frame>Throughout the study period of approximately 5 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Rate per infusion of moderate or severe adverse events (AEs) that may be a result of immune-mediated responses</measure>
    <time_frame>Throughout the study period of approximately 5 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of binding antibodies to rHuPH20</measure>
    <time_frame>Throughout the study period of approximately 5 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of neutralizing antibodies to rHuPH20</measure>
    <time_frame>Throughout the study period of approximately 5 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with a decline of anti-rHuPH20 antibody titers to the antibody titer level at baseline in Study 161403 or Study 161601 and/or to &lt;160 at the study completion or early discontinuation</measure>
    <time_frame>Throughout the study period of approximately 5 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants who have &gt;10,000 titer of binding antibodies to rHuPH20: neutralizing antibodies and cross reactivity with Hyal-1,2 and 4</measure>
    <time_frame>Throughout the study period of approximately 5 years</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">149</enrollment>
  <condition>Chronic Inflammatory Demyelinating Polyradiculoneuropathy</condition>
  <arm_group>
    <arm_group_label>All Study Participants</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>HYQVIA</intervention_name>
    <arm_group_label>All Study Participants</arm_group_label>
    <other_name>IGI 10% with rHuPH20</other_name>
    <other_name>Immune Globulin Infusion 10% (Human) (IGI 10%) with recombinant human hyaluronidase (rHuPH20)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Has completed Epoch 1 of Study 161403 or Study 161601 without CIDP worsening.

          2. If female of childbearing potential, the participant must have a negative pregnancy
             test at baseline and agree to employ adequate birth control measures throughout the
             course of the study.

        Exclusion Criteria:

          1. Participant has a serious medical condition such that the participant's safety or
             medical care would be impacted by participation in this Extension Study

          2. New medical condition that developed during participation in Study 161403 or Study
             161601 that, in the judgment of the investigator, could increase risk to the
             participant or interfere with the evaluation of investigational medicinal product
             (IMP) and/or conduct of the study

          3. Participant is scheduled to participate in another non-Baxalta clinical study
             involving an IP or investigational device during the course of this study

          4. The participant is nursing or intends to begin nursing during the course of the study

          5. Participant has participated in another clinical study involving an investigational
             product (IP) or investigational device within 30 days prior to enrollment (with the
             exception of Study 161403 or Study 161601) or is scheduled to participate in another
             clinical study involving an IP or investigational device during the course of this
             study

          6. The participant is a family member or employee of the investigator
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Steve Glyman, MD</last_name>
    <role>Study Director</role>
    <affiliation>Shire</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Andras Nagy</last_name>
    <phone>617-588-8362</phone>
    <email>andras.nagy@shire.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Groupe Hospitalier Pellegrin - HÃ´pital Pellegrin</name>
      <address>
        <city>Bordeaux Cedex</city>
        <state>Gironde</state>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 2, 2016</study_first_submitted>
  <study_first_submitted_qc>November 2, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 4, 2016</study_first_posted>
  <last_update_submitted>October 19, 2017</last_update_submitted>
  <last_update_submitted_qc>October 19, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 23, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Polyradiculoneuropathy</mesh_term>
    <mesh_term>Polyradiculoneuropathy, Chronic Inflammatory Demyelinating</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Immunoglobulins</mesh_term>
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>gamma-Globulins</mesh_term>
    <mesh_term>Immunoglobulins, Intravenous</mesh_term>
    <mesh_term>Rho(D) Immune Globulin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

